Neurogenomiks Group, Universidad del País Vasco (UPV/EHU), Leioa, Spain.
J Interferon Cytokine Res. 2010 Oct;30(10):727-32. doi: 10.1089/jir.2010.0085.
Interferon-beta (IFN-β) is one of the main first-line disease-modifying drugs indicated for the treatment of multiple sclerosis (MS). The drug exhibits only limited effectiveness, and does not produce clinical benefits in around 20%-50% of patients. The availability of biomarkers would be beneficial for identification of patients at high risk of treatment failure, before initiation of therapy. Over the last 5 years, the search for such biomarkers has intensified and various promising candidates have been uncovered. Here, we review the main attempts undertaken to identify polymorphic variants associated with response to IFN-β therapy in MS by means of candidate gene approaches and whole-genome association scans. Despite substantial progress made in the field, there is still a long way to go before biomarker discoveries can be incorporated into clinical practice to predict IFN-β-responder status in MS patients.
干扰素-β（IFN-β）是治疗多发性硬化症（MS）的主要一线疾病修正药物之一。该药物的疗效有限，大约 20%-50%的患者没有临床获益。生物标志物的出现将有助于在开始治疗前识别治疗失败风险高的患者。在过去的 5 年中，人们对这类生物标志物的研究日益深入，发现了多种有前途的候选物。在这里，我们回顾了通过候选基因方法和全基因组关联扫描来确定与 IFN-β 治疗 MS 反应相关的多态性变异的主要尝试。尽管该领域取得了重大进展，但在将生物标志物发现纳入临床实践以预测 MS 患者对 IFN-β 的反应状态之前，还有很长的路要走。
